Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 999

1.

Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.

Durántez M, López-Vázquez AB, de Cerio AL, Huarte E, Casares N, Prieto J, Borrás-Cuesta F, Lasarte JJ, Sarobe P.

Scand J Immunol. 2009 Feb;69(2):80-9. doi: 10.1111/j.1365-3083.2008.02202.x. Epub 2008 Dec 10.

3.
4.
5.

Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization.

Sandberg JK, Leandersson AC, Devito C, Kohleisen B, Erfle V, Achour A, Levi M, Schwartz S, Kärre K, Wahren B, Hinkula J.

Virology. 2000 Jul 20;273(1):112-9.

6.

Enhanced multiepitope-based vaccines elicit CD8+ cytotoxic T cells against both immunodominant and cryptic epitopes.

Tine JA, Firat H, Payne A, Russo G, Davis SW, Tartaglia J, Lemonnier FA, Demoyen PL, Moingeon P.

Vaccine. 2005 Jan 11;23(8):1085-91.

PMID:
15620483
7.

The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines.

Arlen P, Tsang KY, Marshall JL, Chen A, Steinberg SM, Poole D, Hand PH, Schlom J, Hamilton JM.

Cancer Immunol Immunother. 2000 Dec;49(10):517-29.

PMID:
11129322
8.

Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes.

Ishioka GY, Fikes J, Hermanson G, Livingston B, Crimi C, Qin M, del Guercio MF, Oseroff C, Dahlberg C, Alexander J, Chesnut RW, Sette A.

J Immunol. 1999 Apr 1;162(7):3915-25.

9.

Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.

Buchan S, Grønevik E, Mathiesen I, King CA, Stevenson FK, Rice J.

J Immunol. 2005 May 15;174(10):6292-8.

10.

Induction of specific CTL by MAGE-3/CEA peptide-pulsed dendritic cells from HLA-A2/A24(+) gastrointestinal cancer patients.

Hao X, Shao Y, Ren X, Liu H, Xu Q, Li H, Zhang P, An X, Ren B.

J Cancer Res Clin Oncol. 2002 Sep;128(9):507-15. Epub 2002 Aug 21.

PMID:
12242516
11.

DNA vaccine expressing repeated carcinoembryonic antigen (CEA)(625-667) induces strong immunity in mice.

Li D, Hua S, Fan Y, Xu S, Duan X, Liu L, Che Y, Li S, Tan Y.

Immunol Lett. 2011 Mar 30;135(1-2):124-8. doi: 10.1016/j.imlet.2010.10.012. Epub 2010 Nov 10.

PMID:
21073899
12.

The use of HLA class I tetramers to design a vaccination strategy for melanoma patients.

Palmowski M, Salio M, Dunbar RP, Cerundolo V.

Immunol Rev. 2002 Oct;188:155-63. Review.

PMID:
12445289
15.

A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses.

Conforti A, Peruzzi D, Giannetti P, Biondo A, Ciliberto G, La Monica N, Aurisicchio L.

J Immunother. 2009 Sep;32(7):744-54. doi: 10.1097/CJI.0b013e3181aee1b6.

PMID:
19561534
17.

Identification of a MHC class-II restricted epitope in carcinoembryonic antigen.

Shen L, Schroers R, Hammer J, Huang XF, Chen SY.

Cancer Immunol Immunother. 2004 May;53(5):391-403. Epub 2003 Nov 18.

PMID:
14624313
18.

Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen.

Schütz A, Oertli D, Marti WR, Noppen C, Padovan E, Spagnoli GC, Heberer M, Zajac P.

Cancer Gene Ther. 2001 Sep;8(9):655-61.

19.

Competition between CTL narrows the immune response induced by prime-boost vaccination protocols.

Palmowski MJ, Choi EM, Hermans IF, Gilbert SC, Chen JL, Gileadi U, Salio M, Van Pel A, Man S, Bonin E, Liljestrom P, Dunbar PR, Cerundolo V.

J Immunol. 2002 May 1;168(9):4391-8.

20.

Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1.

Wilson CC, McKinney D, Anders M, MaWhinney S, Forster J, Crimi C, Southwood S, Sette A, Chesnut R, Newman MJ, Livingston BD.

J Immunol. 2003 Nov 15;171(10):5611-23.

Supplemental Content

Support Center